Curriculum Vitae

Last name, First name: Turner, Suzanne **Gender**: Female

Nationality: British

Overall Scientific Expertise:
I have been leading a research group that focusses on the pathogenesis of lymphoma, specifically ALCL since 2005. In that time, we have published pivotal research pointing towards the origins and pathogenesis of this malignancy. In particular, we were the first to demonstrate the thymic origin of ALCL and to show that tumour cells with genetic signatures of thymic progenitors are present in the established tumour acting as 'tumour propagating cells' or 'cancer stem cells'. More latterly, we have been applying these findings to uncovering the pathogenesis and aetiology of BIA-ALCL.

Professional Experience
[Starting with your present occupation, list in reverse chronological order each activity in which you have been engaged. Please copy and paste more rows if needed.]

Years employed from – to	Title of position	Employer – name and location	Areas of professional specialisation♠
2005-present	University reader (Professor)	University of Cambridge, Cambridge, UK	Cellular and molecular tumour biology
2000-2005	Research Associate	Babraham Institute, Cambridge, UK	Cancers of the immune system
1999-2000	Research Associate	AstraZeneca Central Toxicology Laboratory, Manchester, UK	Carcinogenesis and genotoxicity

Specific expertise in the field of the call

In my lab, we have been investigating the pathogenesis and aetiology of BIA-ALCL whereby we have developed cell line and murine models to investigate this unique malignancy. In addition, we are conducting sequencing studies of a collection of BIA-ALCL tumour/capsule/seroma samples with the aim of uncovering the role of carcinogenic exposures (as indicated by chemical analysis of breast implants).

Educational Background

Year	Degree awarded	Educational Institution – name and location	Areas of educational specialisation*
1999	PhD	Paterson Institute for Cancer Research, University of Manchester, UK	Cancer cell biology

1996	Bsc	Salford University	Biochemistry

Memberships in Scientific Advisory Bodies/Committees/Panels *(if any)***:**

- MHRA Plastics and reconstructive surgery expert advisory group (PRASEAG)
- International grant panel, World Cancer Research Fund
- Executive committee member (co-chair paediatric cancer programme; https://crukcambridgecentre.org.uk/research/programmes/paediatric-cancer) CRUK Cambridge Cancer Centre 2015-
- 100,000 Genomes Project, Department of Health, UK, Genomics England Clinical Interpretations Partnerships (GeCIP), Haematological Malignancies, invited scientific lead T cell lymphoma.
- National Cancer Research Institute (NCRI) Lymphoma (Clinical Studies) Group, Paediatric lymphoma sub-group member. Invited national lead for biological studies,
- Children's Cancer and Leukaemia Group (CCLG) Biological Studies Steering Group (BSSG). The BSSG oversees the running of the national tissue bank, applications for tissue and research activities conducted under the auspices of the CCLG.
- Co-chair (Chair of Biology) European Inter-Group for Collaboration into Paediatric NHL (EICNHL) 2016-2022
- Founding member of the European Research Initiative on ALK related malignancies (ERIA) http://www.erialcl.net/
- Invited chair of the international external scientific advisory board for the Childhood, Adolescent and Young Adult NK/T Cell Lymphoma Consortium (CANTLC), a multi-centre Consortium in the USA, 2019

Memberships in Learned Societies *(if any)***:**
British Association for Cancer Research (BACR)
European Association for Cancer Research (EACR)
American Association for Cancer Research (AACR)
International Society for Paediatric Oncology (SIOP)
Children's Cancer and Leukaemia Group (CCLG)

Memberships in Editorial Boards *(if any)***:**
Editorial board member and *Ad Hoc* section editor (lymphoid malignancies) Leukemia, August 2011- January 2014

Biomarker Insights 2017-

List of Publications:
H-index = 21, >1000 citations, 33 original research publications, 2 book chapters, 4 commentaries, 24 reviews, 2 editorials, 12 original research publications currently at various stages of preparation: under review, submitted or under revision.

1. Turner, S.D., Inghirami, G.I., Mirando, R.M. and Kadin, M (2019) Cell of origin and immunological events in the pathogenesis of BIA-ALCL. American Journal of Pathology, doi: 10.1016/j.ajpath.2019.09.005 [IF 4.069]

2. Fritzal, F., Turner, S.D.* and Kenner, L.* (2019) Is Breast Implant-Associated Anaplastic Large Cell Lymphoma (BIA-ALCL) a Hazard of Breast Implant Surgery? Open Biology, 9(4):190006. doi: 10.1098/rsob.190006 [IF 3.89]

3. Turner, S.D. (2019) Anaplastic Large Cell Lymphoma: chapter in Non-Hodgkin Lymphoma in Childhood and Adolescence, Springer International Publishing DOI: 10.1007/978-3-030-11769-6, eBook ISBN: 978-3-030-11769-6, Hardcover ISBN: 978-3-030-11768-9

4. Turner, S.D. (2019) The Cellular Origins of Breast Implant-Associated Anaplastic Large Cell Lymphoma (BIA-ALCL): Implications for Immunogenesis. Aesthetic Surgery Journal, 39(Supplement 1):S21-S27. doi: 10.1093/asj/sjy229 [IF 1.84]

5. Malcolm, T., Hodson, D.J., Macintrye E.A. and Turner, S.D. (2016) Challenging perspectives on the cellular origin of lymphoma. Open Biology, 6(9). pii: 160232 [IF 4.8]

6. Trigg, R.M.,* Lee, L.C.,* Prokoph, N.,* Jahangiri, L., Reynolds C.P., Burke, G.A.A., Probst, N.A., Han, M., Matthews, J.D., Lim, K.K., Manners, E., Martinez, S., Pastor, J., Blanco-Aparicio, C., Merkel, O., Garces de los Fayos Alonso, I., Kodajova, P., Tangermann, S., Högler, S., Luo, J., Kenner, L.* and Turner, S.D.* (2019) PIM1 inhibition enhances the sensitivity of high-risk aberrant 1 ALK-expressing neuroblastoma to ALK inhibition regardless of MYCN status. Nature Communications, DOI: 10.1038/s41467-019-13315-x

7. Prutsch, N., Suske, T., Liang, H.C., Wu, L., Simonitsch- Klupp, I., Alvarez-Hernandez, A., Gurnhofer, E., Schlederer, M., Roos, S., Kornauth, C., Leone, D., Aufinger, A., Hielscher, T., Aberger, F., Stoiber, D., Strobl, B., Müller, M., Jäger, U., Staber, P., Grebien, F., Moriggl, R., Inghirami, G., Sanda, T., Look, A.T., Turner, S.D., Kenner, L. and Merkel, O. (2018) Dependency on the TYK2/STAT1/MCL1 axis in Anaplastic Large Cell Lymphoma. Leukemia Mar;33(3):696-709. doi: 10.1038/s41375-018-0239-1. [IF12.1]

8. Schleussner, N., Merkel, O., Hummel, F., Costanza, M., Huan-Chang Liang, H-C., Romagnani, C., Durek, P., Anagnostopoulos, I., Hummel, M., Jöhrens, K., Niedobitek., A, Griffin, P.R., Woessmann, W., Damm-Welk, C., Hinze, C., Stoiber, D., Gillissen, B., Turner, S.D., Kaergel, E., von Hoff, L., Grau, M., Lenz, G., Dörken, B., Scheidereit, C., Kenner, L., Janz, M., and Mathas, S. (2017) The AP-1 -BATF and -BATF3 module is essential for growth, survival and TH17 / ILC3 skewing of anaplastic large cell lymphoma. Leukemia 32: 1994–2007 doi: 10.1038/s41375-018-0045-9 [IF 12.1]

9. Malcolm, T*., Villarese, P*., Fairbairn, C., Lamant, L., Trinquand, A., Hook, C.E., Burke, G.A.A., Brugieres, L., Hughes K., Payet, D., Merkel, O., Schiefer, A., Ashankyty, I., Mian, S., Wasik, M., Turner, M., Kenner, L., Asnafi, V., Macintyre, E. and Turner, S.D. (2016) NPM-ALK mimics beta selection enabling thymic escape and peripheral lymphoma development. Nature Communications, 7, Article number: 10087 doi:10.1038/ncomms10087 [IF 11.9]

10. Moti, N., Malcolm, T., Hamoudi, R., Mian, S., Garland, G., Hook, C.E., Burke, G.A.A., Wasik, M., Merkel, O., Kenner, L., Laurenti, E., Dick, J.E. and **Turner, S.D.** (2014) Anaplastic Large Cell Lymphoma stem cells possess a gene expression profile reflective of an early thymic progenitor pointing to a primitive cell of origin. **Oncogene**, Apr 2;34(14):1843-52. doi: 10.1038/onc.2014.112 [IF 6.8]